References
- Gottlieb AB, Immunopathogenesis of psoriasis. Arch Dermatol (1997) 133: 781–2.
- Austin LM, Ozawa M, Kikuchi T et al, The majority of epidermal cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon gamma, interleukin-2 and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations. J Inv Dermatol (1999) 113: 752–9.
- Barnes PJ, Karin M, Nuclear factor-Kappa B: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med (1997) 336: 1066–72.
- Ettehadi P, Greaves MW, Wallach D et al, Elevated tumor necrosis factor: alpha biological activity in psor- iatic skin lesions. Cl Exp Dermatol (1994) 96: 146–51.
- Knight DM, Trinh H, Le J et al, Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol (1993) 20: 1443–53.
- Scallon BJ, Arevlo Moore M, Trinh H et al, Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recom- binant transmembrane TNF-alpha and activates immune effector functions. Cytokine (1995) 7: 251–9.
- Ogilvie AL, Antoni C, Dechant C et al, Treatment of psoriatic arthritis with anti-TNF-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol (2001) 144: 587–9.
- Chaudari U, Romano P, Mulcahy LD et al, Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet (2001) 357: 1842–7.
- Kirby B, Marsland AM, Carmichael AJ, Griffiths CE, Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Cl Exp Dermatol (2001) 26: 27–9.
- Tan MH, Gordon M, Lebwohl O et al, Improvement of pyoderma gangrenosum and psoriasis associated with Crohn’s disease with anti-tumor necrosis factor alpha monoclonal antibodies. Arch Dermatol (2001) 137: 930–3.
- Oh CJ, Das KM, Gottlieb AB, Treatment with anti-tumor necrosis factor monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol (2000) 42: 829–30.
- Van der Vleuten CJM, Gerritsen MJP, Steijlen PM et al, A therapeutic approach to erythrodermic psoriasis: a report of a case and a discussion of therapeutic options. Acta Derm Venereol (Stockholm) (1996) 76: 65–7.
- Barone D, Krantz C, Lambert D et al, Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fash- ion. Arthritis Rheum (1999) 42(suppl): S90.
- Scallon B, Cai A, Shealy D et al, New comparison of. two types of TNF-alpha antagonists approved for rheumatoid arthritis. Arthritis Rheum (2000) 43(suppl): S226.
- Mease PH, Goffe BS, Metz J et al, Etanercept in the treatment of psoriatic arthritis and psoriasis: a rando- mized trial. Lancet (2000) 356: 385–90.
- Prodanovich S, Kirsner RS, Taylor R, Treatment of patients hospitalized for psoriasis. In: Kerdel FA, Kirsner RS, (eds.) Inpatient dermatology. Dermatol Clin Philadelphia: W.B. Saunders (2000) 18:425–35.
- Newland MR, Weinstein A, Kerdel F, Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol (2002) 41(7): 449–52.
- Antoni C, Dechant C, Lorenz PD et al, Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthr Rheum (2002) 47(5): 506–12.